CCL2 and metabolic dysfunction-associated steatohepatitis: These data demonstrate that antibody blockade of CD36 and CCL2 prevents the NASH progression in Mettl3-HKO mice and further supports the theory that elevated CD36 and CCL2 contribute to NASH progression in Mettl3-HKO mice.